Abstract
Th1 type polarization has been implicated in the pathogenesis of familial Mediterranean fever (FMF). Interleukin-12 (IL-12) and IL-10 are proinflammatory cytokines, which play crucial role in Th1 and Th2 type immune response, respectively. IL-18 has a dual effect on T cell response: it was recognized as an IFN-γ-inducing factor in T cells; acting in synergy with IL-12, leading to the development of Th1 type immune responses. But, in the absence of IL-12, IL-18 can promote the production of Th2 cytokines and take part in allergic inflammation. The aim of this study is to measure serum levels of IL-10, IL-12, and IL-18 in patients with FMF, and to investigate the relationship of their expressions with FMF attacks. Serum IL-10, IL-12, and IL-18 levels from patients with FMF were investigated. Thirty-one FMF patients with attack-free, 24 FMF patients with attack and 20 healthy controls were enrolled in the study. The levels of IL-10, IL-12p70 and IL-18 were measured by ELISA. Serum IL-10 levels were not different in FMF patients with attack and attack-free, and healthy controls. Serum IL-12 levels in FMF patients both with attack and attack-free were significantly higher than healthy controls (P = 0.002 and P = 0.047, respectively). There were no differences between FMF patients with attack and attack-free with regard to serum IL-12 levels. Serum IL-18 levels in FMF patients with attack and attack-free were significantly higher than healthy controls (P < 0.001 for both groups). With respect to serum IL-18 levels, no difference was found between FMF patients with attack and attack-free. Our results suggest that IL-12 and IL-18 contribute to the establishment of Th1 polarization seen in FMF and play a part in its pathogenesis. Detection of increased levels of IL-12 and IL-18 in patients with inactive disease implies that they seem to assist Th1 activation and subclinical inflammation persisting during the attack-free period of the disease.
Similar content being viewed by others
References
Kang BY, Kim E, Kim TS (2005) Regulatory mechanisms and their therapeutic implications of interleukin-12 production in immune cells. Cell Signal 17:665–673
Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, Presky DH (1998) The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 16:495–521
Watford WT, Moriguchi M, Morinobu A, O’Shea JJ (2003) The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 14(5):361–368
Hasko G, Szabo C (1999) IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses. Br J Pharmacol 127:1295–1304
Williams LM, Ricchetti G, Sarma U, Smallie T, Foxwell BM (2004) Interleukin-10 suppression of myeloid cell activation—a continuing puzzle. Immunology 113:281–292
Asadullah K, Sterry W, Volk HD (2003) Interleukin-10 therapy—review of a new approach. Pharmacol Rev 55:241–269
Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683–765
Liew FY, McInnes IB (2002) Role of interleukin 18 in inflammatory response. Ann Rheum Dis 61:100–102
Yamamura M, Kawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Morita Y, Ohmoto Y, Makino H (2001) İnterferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum 44:275–285
Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 19:423–474
Dai SM, Matsuno H, Nakamura H, Nishioka K, Yudoh K (2004) Interleukin-18 enhances monocyte tumor necrosis factor alpha and, interleukin-1 beta production induced by contact with T lymphocytes: implications in rheumatoid arthritis. Arthritis Rheum 50:432–443
Fujimori Y, Takatsuka H, Takemoto Y, Hara H, Okamura H, Nakanishi K, Kakishita E (2000) Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 109:652–657
Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Miyawaki S, Amano T, Takeuchi T, Makino H (2001) Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still’s disease. Arthritis Rheum 44:550–560
Musabak U, Pay S, Erdem H, Simsek I, Pekel A, Dinc A, Sengul A (2005) Serum interleukin-18 levels in patients with Behçet’s disease: is its expression associated with disease activity or clinical presentations? Rheumatol Int (online)
The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90:797–807
The French FMF Consortium (1997) A candidate gene for familial Mediterranean fever. Nat Genet 17:25–31
Kiraz S, Ertenli I, Arici M, Calguneri M, Haznedaroglu I, Celik I et al (1998) Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever. Clin Exp Rheumatol 16:721–724
Gang N, Drenth JP, Langevitz P, Zemer D, Brezniak N, Pras M et al (1999) Activation of the cytokine network in familial Mediterranean fever. J Rheumatol 26:890–897
Tunca M, Kirkali G, Soyturk M, Akar S, Pepys MB, Hawkins PN (1999) Acute phase response and evolution of familial Mediterranean fever. Lancet 353:1415
Direskeneli H, Ozdogan H, Korkmaz C, Akoglu T, Yazici H (1999) Serum soluble intercellular adhesion molecule 1 and interleukin 8 levels in familial Mediterranean fever. J Rheumatol 26:1983–1986
Korkmaz C, Ozdogan H, Kasapcopur O, Yazici H (2002) Acute phase response in familial Mediterranean fever. Ann Rheum Dis 61:79–81
Notarnicola C, Didelot MN, Seguret F, Demaille J, Touitou I (2002) Enhanced cytokine mRNA levels in attack-free patients with familial Mediterranean fever. Genes Immun 3:43–45
Bagci S, Toy B, Tuzun A, Ates Y, Aslan M, Inal A et al (2004) Continuity of cytokine activation in patients with familial Mediterranean fever. Clin Rheumatol 23:333–337
Haznedaroglu S, Ozturk, Sancak B, Goker B, Onat AM, Bukan N et al (2005) Serum interleukin 17 and interleukin 18 levels in familial Mediterranean fever. Clin Exp Rheumatol 23(4 Suppl 38):S77–S80
Aypar E, Özen S, Okur H, Kutluk T, Besbas N, Bakkaloğlu A (2003) Th1 Polarization in familial Mediterranean fever. J Rheumatol 30:2011–2013
Sackesen C, Bakkaloglu A, Sekerel BE, Özaltın F, Besbas N, Yılmaz E et al (2004) Decreased prevalence of atopy in paediatric patients with familial Mediterranean fever. Ann Rheum Dis 63:187–190
Köklü S, Öztürk MA, Balcı M, Yüksel O, Ertenli İ, Kiraz S (2005) Interferon-gamma levels in familial Mediterranean fever joint bone. Spine 72:38–40
Musabak U, Sengül A, Oktenli C, Pay S, Yesilova Z, Kenar L et al (2004) Does immun activation continue during an attack-free period in familial Mediterranean disease? Clin Exp Immunol 138:526–533
Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1879–1885
Territo MC, Peters RS, Cline MJ (1976) Leukocyte function in familial Mediterranean fever. Am J Hematol 1:307–311
Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H et al (1993) Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet’s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 20:1544–1549
Baykal Y, Saglam K, Yilmaz MI, Taslipinar A, Akinci SB Inal A (2003) Serum sIL-2r, IL-6, IL-10 and TNF-alpha level in familial Mediterranean fever patients. Clin Rheumatol 22:99–101
Oktem S, Yavuzsen TU, Sengul B, Akhunlar H, Akar S, Tunca M (2004) Levels of interleukin-6 (IL-6) and its soluble receptor (sIL-6R) in familial Mediterranean fever (FMF) patients and their first degree relatives. Clin Exp Rheumatol 22(4 Suppl 34):S34–S36
Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C, Kingma DW et al (2000) The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 95:3223–3231
Notarnicola C, Didelot MN, Kone-Paut I, Seguret F, Demaille J, Touitou I (2002) Reduced MEFV messenger RNA expression in patients with familial Mediterranean fever. Arthritis Rheum 46:2785–2793
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Simsek, I., Pay, S., Pekel, A. et al. Serum proinflammatory cytokines directing T helper 1 polarization in patients with familial Mediterranean fever. Rheumatol Int 27, 807–811 (2007). https://doi.org/10.1007/s00296-006-0301-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-006-0301-6